# persona_off · bixbench · bix-24-q2

[All trial-1 traces](../../README.md)

- Trial: **1**; endpoint: **original**; attempt: **1**.
- Native status: **scored**; normalized native score: **0/100**.
- Recorded protocol: `researcher-review-v2`.
- Actor, simulator, and judge: **GPT-6 Astra, low reasoning**.
- Scope: chronological shared messages and handoff fields. Private tool logs, system prompts, evaluator references, and raw API requests are not included.
- A repaired endpoint belongs to the same trial; it is not an independent repeat. Zero scores and missing scientific submissions are retained.

## Shared conversation

### Event 1 — Simulator

**Message**

````text
Inspect the supplied inputs and available repository/tooling only; do not run the full analysis yet. Check counts_raw_unfiltered.csv and sample_layout.csv for gene identifier type, count validity, dimensions, sample matching, group labels, replicates, and any documented treatment, cell-line, dose, or batch information. Report which CBD-versus-control contrasts the metadata supports and any consequential ambiguity rather than inferring undocumented group meanings. Propose an appropriate differential-expression design using padj < 0.05 and |log2FC| > 0.5, followed by separate GO Biological Process enrichment of upregulated and downregulated genes. Describe your proposed gene mapping, tested-gene background, enrichment multiple-testing adjustment, and how you would assess which direction primarily accounts for metabolic enrichment. Identify available annotation resources and any limitations. Return the inspection findings and proposed approach for review before execution.
````

**Interaction**

````text
initial_request
````

**Phase**

````text
initial_inspection
````

**Action**

````text
continue
````

**Approve Approach**

````text
false
````

**Evidence**

````text
The supplied context identifies a raw-count CSV with 30 sample columns and a layout CSV with fileNames, SampleID, and Group; treatment identities, covariates, organism, and gene identifiers remain unverified.
````

**Objectives Open**

````text
[
  "Inspect inputs and establish supported CBD-versus-control contrasts and consequential assumptions.",
  "Agree on the differential-expression and directional GO Biological Process enrichment approach.",
  "Execute the agreed analysis and provide a concise evidence-based conclusion with retained analysis script or notebook."
]
````

### Event 8 — Actor

**Answer**

````text
## Inspection findings
- Only the two input CSVs and task.json are supplied; there is no experimental protocol or annotation file.
- Counts: **63,677 genes × 30 samples**, all unique, unversioned human Ensembl-format gene IDs (`ENSG` plus 11 digits). Species is strongly indicated by identifiers, but no genome/annotation release is documented.
- Every count is a finite, nonnegative integer; no missing counts, duplicated genes, or duplicated sample columns. Counts range from 0 to 906,308. There are **27,954 all-zero genes**, **35,723 genes with any counts**, and **19,042 genes with ≥10 counts in ≥3 samples**.
- Metadata: 30 rows and three fields (`fileNames`, `SampleID`, `Group`), with no missing values or duplicate sample IDs/filenames. Replacing `-` with `_` in SampleID produces an exact, one-to-one match to count columns in the same order.
- There are **three samples per group**, across ten groups: Untreated; Serum_starvation; DMSO; DMSO_Serum_starvation; Cisplatin_IC50; Cisplatin_IC50_Serum_starvation_16h; CBD_IC50; CBD_IC50_Serum_starvation_16h; Cisplatin_IC50_CBD_IC50; Cisplatin_IC50_CBD_IC50_Serum_starvation_16h.
- These are three labeled replicates per group; biological versus technical replication and pairing are not documented. Repeated suffixes 1–3 do not establish matched subjects or batches.
- Library totals range from **8,200,746 (3_1, DMSO)** to **51,875,777 (7_1, CBD_IC50)**. This warrants normalization and sample QC, not automatic sample exclusion.
- Treatment information is limited to group names: CBD/cisplatin at an unspecified IC50, with some serum-starvation groups labeled 16h. No numeric dose, cell-line identity, batch variable, CBD exposure duration, or vehicle matching protocol is provided. The public question supplies CRC context, not specific cell lines.

## Supported contrasts and consequential ambiguity
1. **Proposed primary:** CBD_IC50 versus DMSO (3 versus 3), assuming DMSO is the matched CBD vehicle control. Positive log2FC means higher expression under CBD.
2. **Separate starvation-context analysis:** CBD_IC50_Serum_starvation_16h versus DMSO_Serum_starvation (3 versus 3). The labels permit this contrast, but the control lacks the explicit 16h qualifier, so exact timing equivalence is unverified.
3. CBD_IC50 versus Untreated, and CBD_IC50_Serum_starvation_16h versus Serum_starvation, are available sensitivity contrasts, but may combine CBD and vehicle effects; they are not interchangeable with vehicle-controlled effects.
4. Combination versus cisplatin-only contrasts are available in each starvation context. They address the incremental CBD-associated effect in cisplatin-treated cells, not CBD monotherapy.

I would not pool starvation states or treat cisplatin combinations as CBD-only replicates. The metadata does not establish a single universally intended contrast. My proposed priority is vehicle-controlled CBD monotherapy, with the starvation contrast reported separately and any disagreement retained rather than averaged away.

## Proposed analysis after approval
- Install and use PyDESeq2 (R/DESeq2 is not currently available). Fit a negative-binomial DESeq2-style model with **design ~ Group** across the 30 samples, preserving separate group levels; no undocumented batch or pairing term. Prefilter genes to ≥10 counts in ≥3 samples (19,042 genes from inspection), use median-of-ratios normalization, dispersion estimation, and explicit CBD-minus-control Wald contrasts.
- Perform normalized/VST sample QC, PCA, sample distances, and outlier diagnostics; do not drop samples solely for low library size. Treat replicate independence as an assumption. Record model/software settings and any Cook's-distance or independent-filtering exclusions.
- Use Benjamini–Hochberg gene-level adjusted p-values within each contrast, with alpha 0.05. Select **padj < 0.05 and |log2FC| > 0.5**, then divide into log2FC > 0.5 and log2FC < −0.5. Use unshrunk model coefficients for this requested threshold; any shrinkage would be descriptive only.
- Map unversioned Ensembl IDs directly to human GO annotations, ideally using a downloaded, version-recorded Ensembl/BioMart Ensembl-to-GO table plus the GO ontology. Alternatively use a documented Ensembl-to-Entrez mapping and NCBI human gene2go. Deduplicate gene–term pairs; preserve Ensembl IDs as the counting unit, report unmapped/ambiguous mappings, and do not multiply counts through one-to-many mappings. Symbols are for reporting, not identity matching.
- Use GO **Biological Process** annotations only, exclude NOT annotations where available, and propagate memberships through appropriate is_a/part_of ancestry. Record annotation source, release/download date, evidence policy, and mapping coverage. Include electronic annotations unless a prespecified evidence-restricted sensitivity analysis is warranted.
- Perform separate one-sided hypergeometric/Fisher overrepresentation tests for upregulated and downregulated lists. Use the same contrast-specific background for both directions: genes eligible for DE selection (finite adjusted p-values after filtering/outlier handling) that map to GO BP. Restrict lists and terms to that background; do not use all human genes or the unfiltered count matrix.
- Test BP terms with 10–500 background genes, applying **BH correction across all eligible BP terms separately in each direction and contrast**, including terms with no selected hits as p=1. Enrichment significance: adjusted p < 0.05. Record universe/list sizes, overlaps, odds ratios or fold enrichment, raw p-values, and adjusted p-values.
- Define metabolic BP terms a priori by ancestry under **GO:0008152, metabolic process**, and identify coherent metabolic subprocesses rather than selecting labels after seeing results. Compare up versus down using significant metabolic term patterns, enrichment strength, overlapping gene counts, and the fraction of each directional list involved. Collapse overlapping GO branches for interpretation; raw term counts alone are not decisive because GO terms are highly redundant and list sizes differ. Report a primary direction only if multiple measures support it, and retain mixed/context-specific findings when appropriate. This assesses transcriptional enrichment, not measured metabolic flux or causal metabolic function.

## Tooling and annotation limitations
Python, pandas, NumPy, SciPy, and statsmodels are available. Neither R/Rscript nor PyDESeq2, goatools, gseapy, or mygene is currently installed. curl/wget are available. No local annotation resources were supplied or found in the inspected workspace/cache locations. Ensembl/BioMart, NCBI gene2go plus identifier mappings, and the GO ontology are candidate external resources, **not yet downloaded or verified reachable**. Installation and resource retrieval are prerequisites; I would report failures rather than silently substitute an inappropriate statistical test or opaque gene-set background.

No differential-expression modeling or enrichment has been run. Please approve the proposed primary vehicle-controlled contrast and separate starvation-context analysis (including the documented vehicle/timing assumptions) before execution.
````

**Stage**

````text
plan
````

**Evidence**

````text
CSV inspection: count shape (63677,30), layout shape (30,3), 63677/63677 ENSG-format identifiers, zero duplicate/missing gene IDs, zero nonfinite/negative/noninteger counts; normalized sample IDs match columns exactly; all ten groups contain 3 samples. Only task.json and the two CSV inputs are present. Python module/executable checks found pandas/numpy/scipy/statsmodels, but no R/Rscript or PyDESeq2/GO packages. These are inspection results only, not DE or enrichment outcomes.
````

**Assumptions**

````text
[
  "DMSO is the matched CBD vehicle control; this is plausible from labels but not documented experimentally.",
  "The three samples per group can be modeled as independent replicates; biological/technical status and pairing are unspecified.",
  "Human annotations are appropriate given the ENSG identifier namespace.",
  "The starvation vehicle control is comparable to the explicitly 16h-labeled CBD starvation group; timing equivalence is unverified."
]
````

**Uncertainties**

````text
[
  "No numeric dose, named CRC cell line, batch, genome annotation release, or CBD exposure duration is documented.",
  "External annotation access and PyDESeq2 installation have not been tested.",
  "Different starvation contexts may yield different directional conclusions and should not be pooled."
]
````

### Event 9 — Simulator

**Message**

````text
Approved: execute the proposed analysis with CBD_IC50 versus DMSO as the primary contrast and the vehicle-controlled starvation contrast reported separately. Retain vehicle matching, independent replication, and starvation timing as explicit assumptions rather than established study facts. The group-level model, prefilter, requested DE thresholds, and separate directional GO BP tests with a common contrast-specific tested/annotated background are appropriate. Use the proposed metabolic-process ancestry definition and interpret coherent subprocesses rather than raw redundant GO term counts; distinguish broad metabolic annotations from specific energy, lipid, or other metabolic programs. Verify annotation and software availability, record versions and mapping coverage, and report any consequential deviations rather than silently substituting methods. Execute QC and retain diagnostics without automatic sample exclusion. Return a concise answer to whether upregulation or downregulation primarily drives the CBD-associated metabolic transcriptional effects, with supporting directional DEG counts, enrichment summaries and representative terms with adjusted p-values, and any context dependence. Retain the executed script or notebook and provide its path in artifacts.analysis; set payload.executed_analysis true only after execution. No need to run combination-treatment contrasts unless the primary analyses reveal an uncertainty requiring them.
````

**Interaction**

````text
next_task
````

**Phase**

````text
approach_review
````

**Action**

````text
continue
````

**Approve Approach**

````text
true
````

**Evidence**

````text
Inspection reports valid integer counts, exact metadata matching after sample-name normalization, ten groups with three labeled replicates each, and supported separate CBD/vehicle contrasts. The proposed method meets the requested DE thresholds and GO BP enrichment objective while acknowledging undocumented control matching and replication. No modeling or enrichment has yet been executed, and annotation access remains unverified.
````

**Objectives Open**

````text
[
  "Execute differential expression and sample/model diagnostics.",
  "Execute separate upregulated and downregulated GO BP enrichment with documented annotation and background.",
  "Determine the predominant metabolic transcriptional direction and report starvation-context consistency or differences.",
  "Provide concise final answer and retained executed analysis artifact under the submission contract."
]
````

### Event 22 — Actor

**Answer**

````text
**The direction cannot yet be determined: execution was blocked before differential expression and GO enrichment.** I completed reproducible count validation and sample QC, but cannot supply valid directional DEG counts, enriched terms, or adjusted enrichment p-values without the required software and annotations.

**Blockers verified:** R/Rscript and PyDESeq2 are absent. Package installation failed (first a missing system CA bundle, then DNS resolution failure after a certificate workaround). PyPI, GO, Ensembl, and NCBI hosts all fail DNS resolution. No GO ontology or human gene–GO mapping was supplied or found in the searched local locations. Mapping coverage is therefore unavailable, not zero. No alternative DE method or invented annotation was substituted.

**Executed evidence:** 63,677 genes × 30 samples; 19,042 genes satisfy the approved ≥10 counts in ≥3 samples prefilter. Median-of-ratios QC normalization used 16,877 genes positive in all samples; size factors range 0.289–1.861. PCA on the 500 most variable log2(normalized count + 1) genes explains 22.0%, 11.4%, and 8.6% in PCs 1–3. This is QC, not a fitted DESeq2 variance-stabilizing transform. DMSO sample 3_1 is notably separated on PC3 (28.87 versus −1.69 for both other DMSO samples) and has the lowest library size (8.20 million), warranting attention during eventual model diagnostics. No samples were excluded. Starvation CBD and vehicle samples separate on PC2, but this is not evidence for a particular metabolic direction.

The executed script and sample-level PCA, correlation, distance, normalization, and status outputs are retained. Versions: NumPy 2.4.4, pandas 3.0.2, SciPy 1.16.0, statsmodels 0.14.6.

**Needed to complete the approved analysis:** provision PyDESeq2 with dependencies (or R/DESeq2) plus a human Ensembl-to-GO BP mapping and GO ontology, or restore access to download them. Then retain CBD_IC50 versus DMSO as primary and the starvation vehicle-controlled contrast separately, using the previously approved thresholds/backgrounds. Vehicle matching, independent replication, and starvation timing equivalence remain assumptions. There is no defensible up-versus-down or context-dependence conclusion yet.
````

**Stage**

````text
result
````

**Evidence**

````text
analysis.py executed successfully (exit code 0), producing results/execution.log and five diagnostic/status files. status.json records missing packages and DNS failures for all four resource hosts, plus null (not zero) DE counts and GO results. PCA coordinates: DMSO 3_1 PC3=28.8666; 3_2=-1.6858; 3_3=-1.6857. No DESeq2 model, Wald tests, Cook's diagnostics, or GO tests were executed.
````

**Assumptions**

````text
[
  "DMSO is the matched CBD vehicle control.",
  "Samples within groups represent independent replicates.",
  "DMSO starvation controls are timing-matched to the explicitly 16h-labeled CBD starvation samples."
]
````

**Uncertainties**

````text
[
  "Direction of metabolic transcriptional enrichment is unresolved until valid DE and GO analysis can run.",
  "The unusual DMSO 3_1 QC profile may affect the primary contrast but does not justify automatic exclusion.",
  "Local resource searches were limited to plausible workspace, temporary, system-share, and scratch locations, not an exhaustive scan of every mounted path."
]
````

### Event 23 — Simulator

**Message**

````text
Conclude with the explicit limitation: the supplied data have not yielded a defensible upregulation-versus-downregulation conclusion because differential expression and GO BP enrichment could not be executed. Retain the concise blocked-analysis answer and analysis.py as execution evidence. Make clear that executed_analysis=true refers only to executed validation/QC, alongside the partial-analysis status, and not completed DE or enrichment. Do not interpret PCA separation as metabolic direction or supply unsupported results.
````

**Interaction**

````text
conclude
````

**Phase**

````text
result_review
````

**Action**

````text
stop
````

**Approve Approach**

````text
false
````

**Evidence**

````text
Reported execution produced validation and QC outputs, but verified missing DE software, failed installation/network access, and absent GO resources prevented the required analyses. The handoff transparently reports null DE/GO results and preserves an executed script. Further requests cannot reasonably resolve the documented provisioning blockers within the available environment.
````

**Objectives Open**

````text
[
  "Determine directional DEGs using padj < 0.05 and |log2FC| > 0.5 once DE software is available.",
  "Perform directional GO BP enrichment with human annotations and determine the predominant metabolic transcriptional direction, retaining starvation-context distinctions."
]
````

## Provenance

````text
{
  "source_run": "runs/openai-astra-top2-first-pass",
  "repair_run": "runs/repair-1-openai-astra-top2-first-pass",
  "event_log": "runs/openai-astra-top2-first-pass/episodes/bixbench_bix-24-q2-d1d4d162f268/persona_off/attempt-1/output/bixbench_bix-24-q2-d1d4d162f268/controller/events.jsonl",
  "event_log_sha256": "b3a8fd1f36457f58f775cef0af236abfef4986dd7ce279c21ca95c5f891ac1ea",
  "models": {
    "actor": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "researcher": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    },
    "judge": {
      "model": "gpt-6-astra",
      "provider": "openai",
      "reasoning_effort": "low"
    }
  }
}
````
